SCHEMBL23218124

SCHEMBL23218124

CCOC(=O)Cc1ccc(C2CC2)cc1OCc1coc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFD P00746 7/20 0.42
F11 P03951 2/20 0.39
KLKB1 P03952 2/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
F7 P08709 1/20 0.39
TPSB2 P20231 1/20 0.39
FFAR1 O14842 1/20 0.37
MAP4K4 O95819 2/20 0.34
GAA P10253 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
SYK P43405 1/20 0.32
CASP1 P29466 1/20 0.32
ALDH2 P05091 1/20 0.32
GPBAR1 Q8TDU6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852642 1.00 CFD (0.42) CFDF11KLKB1PLGPLAU
SCHEMBL23218676 0.90 CFD (0.48) CFDF11KLKB1PLGPLAU
SCHEMBL29852445 0.90 CFD (0.48) CFDF11KLKB1PLGPLAU
SCHEMBL29591390 0.90 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL23218047 0.90 CFD (0.51) CFDF11KLKB1PLGPLAU
SCHEMBL23218909 0.89 CFD (0.45) CFDF11KLKB1PLGPLAU
SCHEMBL29852594 0.89 CFD (0.45) CFDF11KLKB1PLGPLAU
SCHEMBL29852675 0.88 CFD (0.43) CFDF11KLKB1PLGPLAU
SCHEMBL23218797 0.88 CFD (0.43) CFDF11KLKB1PLGPLAU
SCHEMBL23218586 0.88 CFD (0.45) CFDF11KLKB1PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885KLKB1 370/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885KLKB1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.